Journal Article

A Smo/Gli Multitarget Hedgehog Pathway Inhibitor Impairs Tumor Growth

Caimano, Miriam, Infante, Paola, Loricchio, Elena, Quaglio, Deborah, Maroder, Marella, Botta, Bruno, Lospinoso Severini, Ludovica, Ghirga, Francesca, Bufalieri, Francesca, Mori, Mattia, Romeo, Isabella, Balducci, Silvia, Basili, Irene, Moretti, Marta, Di Marcotullio, Lucia

2019

Overview

Pharmacological Hedgehog (Hh) pathway inhibition has emerged as a valuable anticancer strategy. A number of small molecules able to block the pathway at the upstream receptor Smoothened (Smo) or the downstream effector glioma-associated oncogene 1 (Gli1) has been designed and developed. In a recent study, we exploited the high versatility of the natural isoflavone scaffold for targeting the Hh signaling pathway at multiple levels showing that the simultaneous targeting of Smo and Gli1 provided synergistic Hh pathway inhibition stronger than single administration. This approach seems to effectively overcome the drug resistance, particularly at the level of Smo. Here, we combined the pharmacophores targeting Smo and Gli1 into a single and individual isoflavone, compound 22, which inhibits the Hh pathway at both upstream and downstream level. We demonstrate that this multitarget agent suppresses medulloblastoma growth in vitro and in vivo through antagonism of Smo and Gli1, which is a novel mechanism of action in Hh inhibition.

• Publisher: MDPI AG,MDPI
• Subject: Brain cancer / Drug resistance / Fibroblasts / Gene amplification / Gene expression / Glioma / Hedgehog protein / Isoflavones / Kinases / Ligands / Medical prognosis / Medulloblastoma / Metastasis / Mutation / Pharmacophores / Signal transduction / Tumorigenesis / Tumors